Sterling Biotech Limited announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported net sales of INR 104,083.8 million compared with INR 92,937.7 million for the same period a year ago. Loss from operation before other income, finance cost and exceptional items was INR 608.306 million compared with INR 639.405 million for the same period a year ago. Loss from ordinary activities before tax was INR 103,163.6 million compared with INR 100,140.5 million for the same period a year ago. Net loss was INR 103.163.6 million or INR 2.38 per diluted share before and after extraordinary items compared with INR 100.140.5 million or INR 2.31 per diluted share before and after extraordinary items for the same period a year ago. For the nine months, the company reported net sales of INR 301,674.3 million, loss from operation before other income, finance cost and exceptional items was INR 187,298.4 million, loss from ordinary activities before tax was INR 300,215.4 million and net loss was INR 300,215.4 million or INR 6.93 per diluted share before and after extraordinary items.